39289 Investors following Cipla. Share this News with them.
0
Like this story, share it with millions of investors on M3
Glivec: Novartis objects to bench composition
Swiss drug-maker Novartis has objected to the presence of former Controller-General of Patents, Mr S. Chandrasekaran, as a Technical Member on the Intellectual Property Appellate Board (IPAB).
Swiss drug-maker Novartis has objected to the presence of former Controller-General of Patents, Mr S. Chandrasekaran, as a Technical Member on the Intellectual Property Appellate Board (IPAB).
This was the IPAB's first hearing on the rejection of Novartis's patent application on its cancer drug, Glivec.
"The newly-appointed technical member of the appellate board is the former Controller-General of the Indian Patent Office, who was responsible for the original decision on the Glivec patent in 2006 and was acting as a party in the recent Court case reviewing the decision of the Indian Patent Office to reject our Glivec patent filing," Novartis said in a statement on Monday.
This was the IPAB's first hearing on the rejection of Novartis's patent application on its cancer drug, Glivec. 
